High Tech Pharm Co Ltd
KOSDAQ:106190
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/OCF
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Valuation Scenarios
If P/OCF returns to its 3-Year Average (12.5), the stock would be worth ₩19 952.52 (0% upside from current price).
| Scenario | P/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 12.4 | ₩19 900 |
0%
|
| 3-Year Average | 12.5 | ₩19 952.52 |
+0%
|
| 5-Year Average | 9.2 | ₩14 764.81 |
-26%
|
| Industry Average | 15.3 | ₩24 530.29 |
+23%
|
| Country Average | 9 | ₩14 391.44 |
-28%
|
Forward P/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | P/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| KR |
H
|
High Tech Pharm Co Ltd
KOSDAQ:106190
|
211.6B KRW | 12.4 | 18.4 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
835.2B USD | 48.8 | 39.7 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.8B USD | 22.1 | 25.8 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 13.7 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.7B GBP | 19.7 | 28.1 | |
| CH |
|
Novartis AG
SIX:NOVN
|
218.2B CHF | 14.3 | 19.6 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
276.9B USD | 16.6 | 14.9 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 907.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 9.8 | 11.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.5B USD | 13 | 19.6 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
116.3B USD | 8.2 | 16.5 |
Market Distribution
| Min | 0.2 |
| 30th Percentile | 4.2 |
| Median | 9 |
| 70th Percentile | 16.6 |
| Max | 2 215 132.4 |
Other Multiples
High Tech Pharm Co Ltd
Glance View
HIGH TECH PHARM Co., Ltd. engages in the manufacture and sale of raw materials for injectable antibiotic products. The company is headquartered in Chungju, Chungcheongbuk-Do and currently employs 99 full-time employees. The company went IPO on 2010-07-28. CO., LTD. is a Korea-based company mainly engaged in the manufacture of antibiotic pharmaceutical ingredients for injections. The firm's products include sterile imipenem, sterile cilastatin sodium, sterile blended imipenem and cilastatin sodium, injectable sterile meropenem, injectable sterile panipenem, faropenem and others. The firm distributes its products within domestic market and to overseas markets.
